ZA201701664B - Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer - Google Patents
Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancerInfo
- Publication number
- ZA201701664B ZA201701664B ZA2017/01664A ZA201701664A ZA201701664B ZA 201701664 B ZA201701664 B ZA 201701664B ZA 2017/01664 A ZA2017/01664 A ZA 2017/01664A ZA 201701664 A ZA201701664 A ZA 201701664A ZA 201701664 B ZA201701664 B ZA 201701664B
- Authority
- ZA
- South Africa
- Prior art keywords
- predictive
- colorectal cancer
- metastatic colorectal
- angiogenic therapy
- prognostic biomarkers
- Prior art date
Links
- 239000000092 prognostic biomarker Substances 0.000 title 2
- 206010052358 Colorectal cancer metastatic Diseases 0.000 title 1
- 238000011122 anti-angiogenic therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051091P | 2014-09-16 | 2014-09-16 | |
| US201562099630P | 2015-01-05 | 2015-01-05 | |
| PCT/US2015/049279 WO2016044041A1 (en) | 2014-09-16 | 2015-09-10 | Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201701664B true ZA201701664B (en) | 2018-05-30 |
Family
ID=54207741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/01664A ZA201701664B (en) | 2014-09-16 | 2017-03-08 | Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10525104B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3194974B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6692358B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102471057B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107076749B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015318207B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2960890A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA036671B1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL250905B (cg-RX-API-DMAC7.html) |
| MX (1) | MX382673B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016044041A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201701664B (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014158287A2 (en) | 2013-03-14 | 2014-10-02 | Otraces Inc. | A method for improving disease diagnosis using measured analytes |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| EP3405896A4 (en) | 2016-01-22 | 2019-09-25 | Otraces Inc. | SYSTEMS AND METHOD FOR IMPROVED DIAGNOSIS OF ILLNESSES |
| AU2018245602B2 (en) | 2017-03-31 | 2021-07-22 | Hirotsu Bio Science Inc. | Method for predicting therapeutic effect and/or recurrence monitoring in cancer patients |
| EA202091786A1 (ru) | 2018-01-26 | 2020-10-20 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Способы и композиции для лечения ангиогенных расстройств с применением агентов против фрэс |
| WO2019169341A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| WO2020165483A1 (es) * | 2019-02-15 | 2020-08-20 | Universidad de Córdoba | Método de predicción de respuesta a tratamiento del cáncer con agentes antiangiogénicos |
| EP3997704A4 (en) * | 2019-07-13 | 2023-07-19 | Otraces Inc. | IMPROVEMENT OF DIAGNOSIS FOR VARIOUS DISEASES USING ACTIVE PROTEINS OF A TUMOR MICROAREA |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| US20220390456A1 (en) * | 2019-10-17 | 2022-12-08 | Board Of Regents, The University Of Texas System | Small extracellular vesicle-associated vegf as a predictor for therapeutic responses |
| MX2022006241A (es) | 2019-11-25 | 2022-08-22 | Univ California | Inhibidores de vegf de accion prolongada para la neovascularizacion intraocular. |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| CN101283280A (zh) * | 2005-08-18 | 2008-10-08 | Zadec私人有限公司 | 用于诊断结直肠癌的蛋白质标记和所述标记作为所述癌症类型治疗的药物靶点的用途 |
| EP2464366A2 (en) * | 2009-08-14 | 2012-06-20 | Allergan, Inc. | Methods of treating cancer using growth factor retargeted endopeptidases |
| SG10201500479XA (en) * | 2010-01-19 | 2015-03-30 | Hoffmann La Roche | Tumor Tissue Based Biomarkers For Bevacizumab Combination Therapies |
| MX2013000676A (es) * | 2010-07-19 | 2013-02-27 | Hoffmann La Roche | Metodo para identificar pacientes con probabilidad incrementada de responder a una terapia anti-cancer. |
| JO3283B1 (ar) * | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
-
2015
- 2015-09-10 EP EP15771819.8A patent/EP3194974B1/en active Active
- 2015-09-10 US US15/509,461 patent/US10525104B2/en active Active
- 2015-09-10 CN CN201580049558.1A patent/CN107076749B/zh active Active
- 2015-09-10 MX MX2017003387A patent/MX382673B/es unknown
- 2015-09-10 JP JP2017533704A patent/JP6692358B2/ja active Active
- 2015-09-10 KR KR1020177007326A patent/KR102471057B1/ko active Active
- 2015-09-10 CA CA2960890A patent/CA2960890A1/en active Pending
- 2015-09-10 EA EA201790549A patent/EA036671B1/ru unknown
- 2015-09-10 AU AU2015318207A patent/AU2015318207B2/en active Active
- 2015-09-10 WO PCT/US2015/049279 patent/WO2016044041A1/en not_active Ceased
-
2017
- 2017-03-02 IL IL250905A patent/IL250905B/en active IP Right Grant
- 2017-03-08 ZA ZA2017/01664A patent/ZA201701664B/en unknown
-
2019
- 2019-11-21 US US16/690,459 patent/US11439683B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL250905A0 (en) | 2017-04-30 |
| MX382673B (es) | 2025-03-13 |
| US20200129589A1 (en) | 2020-04-30 |
| AU2015318207A1 (en) | 2017-04-06 |
| MX2017003387A (es) | 2018-01-30 |
| JP6692358B2 (ja) | 2020-05-13 |
| US10525104B2 (en) | 2020-01-07 |
| AU2015318207B2 (en) | 2021-11-04 |
| US11439683B2 (en) | 2022-09-13 |
| EP3194974B1 (en) | 2019-10-23 |
| US20170281725A1 (en) | 2017-10-05 |
| JP2017530372A (ja) | 2017-10-12 |
| IL250905B (en) | 2019-12-31 |
| KR102471057B1 (ko) | 2022-11-28 |
| CA2960890A1 (en) | 2016-03-24 |
| EP3194974A1 (en) | 2017-07-26 |
| CN107076749A (zh) | 2017-08-18 |
| KR20170055972A (ko) | 2017-05-22 |
| EA036671B1 (ru) | 2020-12-07 |
| EA201790549A1 (ru) | 2017-07-31 |
| WO2016044041A1 (en) | 2016-03-24 |
| CN107076749B (zh) | 2020-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201701664B (en) | Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer | |
| SG11201607448PA (en) | Determining cancer agressiveness, prognosis and responsiveness to treatment | |
| GB2545361B (en) | Methods of assessing colorectal cancer status | |
| IL253756B (en) | A panel of biomarkers for cancer detection | |
| ZA201701753B (en) | Biomarkers for assessing breast cancer | |
| IL244510A0 (en) | Cancer biomarkers and their uses | |
| EP3245302B8 (en) | Mirna-based predictive models for diagnosis and prognosis of prostate cancer | |
| IL251204A0 (en) | Biomarkers and predictive methods | |
| IL267315A (en) | Methods of determining colorectal cancer status in an individual | |
| ZA201802481B (en) | Novel biomarkers and methods of treating cancer | |
| GB201500584D0 (en) | Cancer biomarkers | |
| GB201322800D0 (en) | Prostate cancer biomarkers | |
| IL242551A (en) | Expectation markers for cancer treatment | |
| SG11201601234TA (en) | Circulating cancer biomarker and its use | |
| GB201417281D0 (en) | Methods and devices relating to the detection of oral cancer biomarkers | |
| EP2972376A4 (en) | Methods for determining prognosis of colorectal cancer | |
| GB201619808D0 (en) | Biomarkers for the prognosis and diagnosis of cancer | |
| SG10202103525UA (en) | Cancer biomarkers and methods of use | |
| GB201617722D0 (en) | Method for determining prognosis of cancer | |
| GB201306394D0 (en) | Cancer biomarker | |
| PL3268744T3 (pl) | PD-ECGF jako biomarker raka | |
| EP3060914A4 (en) | Methods of determining breast cancer prognosis | |
| GB201413577D0 (en) | Metastatic prognostic biomarker | |
| GB201407003D0 (en) | Biomarkers for prostate cancer | |
| GB201402559D0 (en) | Biomarkers for prostate cancer |